MONNIER R, DEGRASSAT-THEAS A, PARENT DE CURZON O, SINEGRE M
UF Études Médico-Economiques et Référentiels, Service Evaluations Pharmaceutiques et Bon Usage, AGEPS, AP-HP
Objective
In France, a forecast growth rate in spending related to the list of expensive hospital drugs, funded in addition to DRG-based payment, is determined annually (2% in 2012)
If hospitals exceed the rate, they will be controlled, based on the proper use of drugs
The objective is to question the relevance of this national growth rate as a regulation too.